Skip to main content
SpringerLink
Log in

Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy

  • Case Report
  • Published:
Journal of Orthopaedic Science

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA, Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–99.

    Article  PubMed  CAS  Google Scholar 

  2. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032–45.

    Article  PubMed  CAS  Google Scholar 

  3. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1555–65.

    Article  PubMed  CAS  Google Scholar 

  4. Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res. 2009;467(7):1921–6.

    Article  PubMed  Google Scholar 

  5. Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med. 2010;362(19):1825–7.

    Article  PubMed  CAS  Google Scholar 

  6. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009;122(2 Suppl):S14–21.

    Article  PubMed  CAS  Google Scholar 

  7. Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2010;468(7):1991–6.

    Article  PubMed  Google Scholar 

  8. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89(3):349–53.

    Article  PubMed  Google Scholar 

  9. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury. 2008;39(2):224–31.

    Article  PubMed  Google Scholar 

  10. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358(12):1304–6.

    Article  PubMed  CAS  Google Scholar 

  11. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90(3):1294–301.

    Article  PubMed  CAS  Google Scholar 

  12. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72(2):161–8.

    Article  CAS  Google Scholar 

  13. Somford MP, Geurts GF, den Teuling JW, Thomassen BJ, Draijer WF. Long-term alendronate use not without consequences? Int J Rheumatol. 2009.

  14. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9(8):1137–41.

    Article  PubMed  CAS  Google Scholar 

  15. Kwek EB, Koh JS, Howe TS. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359(3):316–7.

    Article  PubMed  CAS  Google Scholar 

  16. Japanese Guidelines for the Prevention and Treatment of Osteoporosis 2006 edition. Life Science Publishing, Tokyo, 2006:73–102 (in Japanese).

  17. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25(11):2267–94.

    Article  PubMed  Google Scholar 

  18. Das De S, Setiobudi T, Shen L, Das De S. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92(5):679–86.

    Article  PubMed  CAS  Google Scholar 

  19. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24(10):1736–40.

    Article  PubMed  Google Scholar 

  20. Lee P, Seibel MJ. More on atypical fractures of the femoral diaphysis. N Engl J Med. 2008;359(3):317.

    PubMed  CAS  Google Scholar 

  21. Sims SH. Subtrochanteric femur fractures. Orthop Clin North Am. 2002;33(1):113–26.

    Article  PubMed  Google Scholar 

  22. Online version of Gray’s anatomy. Available at http://www.bartleby.com/107/59.html. Accessed Oct 20, 2010.

  23. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15(4):613–20.

    Article  PubMed  CAS  Google Scholar 

  24. Medicines and Healthcare Products Regulatory Agency (MHRA). Bisphosphonate: atypical stress fractures. Drug safety update 2 (8). Available at http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON041211. Accessed Oct 13, 2010.

  25. Lin JH, Duggan DE, Chen IW, Ellsworth RL. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos. 1991;19(5):926–32.

    PubMed  CAS  Google Scholar 

  26. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, LE Wehren, Lombardi A, Santora AC, Cummings SR, FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.

    Article  PubMed  CAS  Google Scholar 

  27. Noth I, Strek ME, Leff AR. Churg–Strauss syndrome. Lancet. 2003;361:587–94.

    Article  PubMed  Google Scholar 

  28. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009;24(6):1095–102.

    Article  PubMed  CAS  Google Scholar 

  29. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC, Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–71.

    Article  PubMed  CAS  Google Scholar 

  30. Dobnig H, Stepan JJ, Burr DB, Li J, Michalská D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2009;24(12):1998–2006.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We wish to thank Ms. Yoko Kasai for the preparation of the histological analysis and Dr. Kensaku Abe for his assistance in performing the surgery.

Conflict of interest

Each author certifies that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with this article.

Author information

Authors and Affiliations

  1. Department of Orthopaedics Surgery, Graduate School of Medical Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan

    Yoshitomo Kajino, Tamon Kabata, Koji Watanabe & Hiroyuki Tsuchiya

Authors
  1. Yoshitomo Kajino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tamon Kabata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koji Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroyuki Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshitomo Kajino.

About this article

Cite this article

Kajino, Y., Kabata, T., Watanabe, K. et al. Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy. J Orthop Sci 17, 313–318 (2012). https://doi.org/10.1007/s00776-011-0085-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00776-011-0085-8

Keywords

Search

Navigation